Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
1 other identifier
interventional
600
1 country
115
Brief Summary
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Nov 2004
115 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2004
CompletedFirst Submitted
Initial submission to the registry
February 17, 2005
CompletedFirst Posted
Study publicly available on registry
February 18, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2007
CompletedOctober 28, 2016
October 1, 2016
2.2 years
February 17, 2005
October 26, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
measure of lung function and quality of life in patients with COPD
Secondary Outcomes (1)
exacerbations in patients with COPD
Study Arms (1)
Arm 1
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Diagnosis of COPD and a history of cigarette smoking.
You may not qualify if:
- Significant heart or lung disease not associated with COPD.
- Significant stomach or intestinal disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- GlaxoSmithKlinelead
Study Sites (115)
GSK Investigational Site
Birmingham, Alabama, 35209, United States
GSK Investigational Site
Jasper, Alabama, 35501, United States
GSK Investigational Site
Phoenix, Arizona, 85006, United States
GSK Investigational Site
Tempe, Arizona, 85282, United States
GSK Investigational Site
Berkeley, California, 94705, United States
GSK Investigational Site
Carmichael, California, 95608, United States
GSK Investigational Site
Fullerton, California, 92835, United States
GSK Investigational Site
Long Beach, California, 90806, United States
GSK Investigational Site
Long Beach, California, 90822, United States
GSK Investigational Site
Los Angeles, California, 90048, United States
GSK Investigational Site
Murrieta, California, 92562, United States
GSK Investigational Site
Rancho Mirage, California, 92270, United States
GSK Investigational Site
Riverside, California, 92805, United States
GSK Investigational Site
Sacramento, California, 95823, United States
GSK Investigational Site
San Diego, California, 92103, United States
GSK Investigational Site
San Diego, California, 92120, United States
GSK Investigational Site
San Jose, California, 95117, United States
GSK Investigational Site
Sepulveda, California, 91343, United States
GSK Investigational Site
Stockton, California, 95207, United States
GSK Investigational Site
Torrance, California, 90509, United States
GSK Investigational Site
Vista, California, 92083, United States
GSK Investigational Site
Walnut Creek, California, 94598, United States
GSK Investigational Site
Boulder, Colorado, 80304, United States
GSK Investigational Site
Colorado Springs, Colorado, 80907, United States
GSK Investigational Site
Denver, Colorado, 80230, United States
GSK Investigational Site
Englewood, Colorado, 80112, United States
GSK Investigational Site
Fort Collins, Colorado, 80528, United States
GSK Investigational Site
Wheat Ridge, Colorado, 80033, United States
GSK Investigational Site
Hartford, Connecticut, 06105, United States
GSK Investigational Site
Stamford, Connecticut, 06902, United States
GSK Investigational Site
Waterbury, Connecticut, 06708, United States
GSK Investigational Site
Aventura, Florida, 33180, United States
GSK Investigational Site
Brandon, Florida, 33511, United States
GSK Investigational Site
DeLand, Florida, 32720, United States
GSK Investigational Site
Fort Lauderdale, Florida, 33316, United States
GSK Investigational Site
Largo, Florida, 33770, United States
GSK Investigational Site
Longwood, Florida, 32779, United States
GSK Investigational Site
Melbourne, Florida, 32935, United States
GSK Investigational Site
Panama City, Florida, 32405, United States
GSK Investigational Site
Pensacola, Florida, 32504, United States
GSK Investigational Site
Tamarac, Florida, 33321, United States
GSK Investigational Site
Tampa, Florida, 33613, United States
GSK Investigational Site
West Palm Beach, Florida, 33409, United States
GSK Investigational Site
Atlanta, Georgia, 30342, United States
GSK Investigational Site
Decatur, Georgia, 30033, United States
GSK Investigational Site
Coeur d'Alene, Idaho, 83814, United States
GSK Investigational Site
Normal, Illinois, 61761, United States
GSK Investigational Site
Evansville, Indiana, 47710, United States
GSK Investigational Site
South Bend, Indiana, 46617, United States
GSK Investigational Site
Wichita, Kansas, 67207, United States
GSK Investigational Site
Madisonville, Kentucky, 42431, United States
GSK Investigational Site
Lafayette, Louisiana, 70503, United States
GSK Investigational Site
New Orleans, Louisiana, 70119, United States
GSK Investigational Site
Slidell, Louisiana, 70461, United States
GSK Investigational Site
Sunset, Louisiana, 70584, United States
GSK Investigational Site
Boston, Massachusetts, 02135, United States
GSK Investigational Site
Cadillac, Michigan, 49601, United States
GSK Investigational Site
Minneapolis, Minnesota, 55402, United States
GSK Investigational Site
Jefferson City, Missouri, 65109, United States
GSK Investigational Site
Saint Charles, Missouri, 63301, United States
GSK Investigational Site
St Louis, Missouri, 63122, United States
GSK Investigational Site
St Louis, Missouri, 63141, United States
GSK Investigational Site
Billings, Montana, 59102, United States
GSK Investigational Site
Missoula, Montana, 59808, United States
GSK Investigational Site
Las Vegas, Nevada, 89104, United States
GSK Investigational Site
Cherry Hill, New Jersey, 08003, United States
GSK Investigational Site
Bronxville, New York, 10708, United States
GSK Investigational Site
Cortland, New York, 14850, United States
GSK Investigational Site
Larchmont, New York, 10538, United States
GSK Investigational Site
New York, New York, 10016, United States
GSK Investigational Site
Chapel Hill, North Carolina, 27599, United States
GSK Investigational Site
Charlotte, North Carolina, 28207, United States
GSK Investigational Site
Elizabeth City, North Carolina, 27909, United States
GSK Investigational Site
High Point, North Carolina, 27262, United States
GSK Investigational Site
Statesville, North Carolina, 28625, United States
GSK Investigational Site
Chardon, Ohio, 44024, United States
GSK Investigational Site
Columbus, Ohio, 43215, United States
GSK Investigational Site
Dayton, Ohio, 45406, United States
GSK Investigational Site
Sylvania, Ohio, 43560, United States
GSK Investigational Site
Lake Oswego, Oregon, 97035, United States
GSK Investigational Site
Medford, Oregon, 97504, United States
GSK Investigational Site
Portland, Oregon, 97213, United States
GSK Investigational Site
Allentown, Pennsylvania, 18103, United States
GSK Investigational Site
Downington, Pennsylvania, 19335, United States
GSK Investigational Site
Elverson, Pennsylvania, 19520, United States
GSK Investigational Site
Erie, Pennsylvania, 16508, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, 15213, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, 15218, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, 15243, United States
GSK Investigational Site
Swarthmore, Pennsylvania, 19081, United States
GSK Investigational Site
East Providence, Rhode Island, 02914, United States
GSK Investigational Site
Charleston, South Carolina, 29406-7108, United States
GSK Investigational Site
Gaffney, South Carolina, 29340, United States
GSK Investigational Site
Greer, South Carolina, 29651, United States
GSK Investigational Site
Simpsonville, South Carolina, 29681, United States
GSK Investigational Site
Spartanburg, South Carolina, 29303, United States
GSK Investigational Site
Bristol, Tennessee, 37620, United States
GSK Investigational Site
Chattanooga, Tennessee, 37403, United States
GSK Investigational Site
Johnson City, Tennessee, 37601, United States
GSK Investigational Site
Knoxville, Tennessee, 37920, United States
GSK Investigational Site
Corsicana, Texas, 75110, United States
GSK Investigational Site
Dallas, Texas, 75246, United States
GSK Investigational Site
Fort Worth, Texas, 76104, United States
GSK Investigational Site
San Antonio, Texas, 78205, United States
GSK Investigational Site
San Antonio, Texas, 78217, United States
GSK Investigational Site
San Antonio, Texas, 78229, United States
GSK Investigational Site
Salt Lake City, Utah, 84102, United States
GSK Investigational Site
Richmond, Virginia, 23225, United States
GSK Investigational Site
Richmond, Virginia, 23229, United States
GSK Investigational Site
Bellingham, Washington, 98225, United States
GSK Investigational Site
Spokane, Washington, 99204, United States
GSK Investigational Site
Spokane, Washington, 99207, United States
GSK Investigational Site
Tacoma, Washington, 98405, United States
GSK Investigational Site
Morgantown, West Virginia, 26505, United States
GSK Investigational Site
Milwaukee, Wisconsin, 53209-0996, United States
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
GSK Clinical Trials
GlaxoSmithKline
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 17, 2005
First Posted
February 18, 2005
Study Start
November 1, 2004
Primary Completion
January 1, 2007
Study Completion
January 1, 2007
Last Updated
October 28, 2016
Record last verified: 2016-10
Data Sharing
- IPD Sharing
- Will share
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.